Dayanna Hartmann Cambruzzi Mendes
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Dayanna Hartmann Cambruzzi Mendes has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
- Juliana Sartori Bonini
Universidade Estadual do Centro-Oeste
3 shared publications - Anne Karine Bosetto Fiebrantz
Univ Estadual Centro Oeste, Dept Farm, Lab Neuropsicofarmacol, BR-85040167 Guarapuava, Parana, Brazil
2 shared publications - Bárbara Luisa Fermino
Bacharel em Farmácia, Mestre em Ciências Farmacêuticas
2 shared publications - Elizama de Gregório
Department of Medicine, Postgraduate Program in Development and Society (PPGDS), University of Alto Vale Do Rio Do Peixe (UNIARP), Caçador, Brazil
2 shared publications - Flávia Ivanski
Department of Physiotherapy, Campus CEDETEG, Midwest State University, Guarapuava, PR, 85015-430, Brazil
2 shared publications - Guilherme Barroso Langoni De Freitas
Postgraduate Program in Pharmacology, Federal University of Piauí, Ministro Petrônio Portella University Campus,Piauí, Brazil
2 shared publications
Latest Publications
- 26 May 2023
- Published by Uniao Atlantica de Pesquisadores in Peer Review
- Vol. 5 (10) , 273-297
Mapeamento das intoxicações por agroquímicos no estado do Paraná
Todos os casos de intoxicação exógena são eventos de notificação compulsória, com preenchimento semanal do Sistema de Informação de Agravos de Notificação (Sinan), no entanto, uma estimativa de que apenas 20% dos casos são de fato notificados. Por meio de uma análise documental retrospectiva, descritiva, quantitativa, longitudinal entre 2015 e 2020, foi realizada a tabulação dos dados do Sinan, Siagro, ADAPAR e IBGE, e foram determinadas variáveis relevantes para a melhor compreensão do cenário paranaense atual quanto à comercialização e ao uso de agroquímicos, bem como às intoxicações exógenas. Obteve-se um cenário amplamente distorcido no que se refere à incidência geográfica dos agravos de saúde caracterizados como intoxicações exógenas, além disso, foi identificado um importante pico de notificações após a implantação da portaria que torna compulsória a notificação desse tipo de evento, ainda que haja uma importante incidência média de eventos cujas causas foram listadas como ignorado ou em branco (6,96%), além de volumes alarmantes de agroquímicos comercializados dentre as classes menos potencialmente.
- 26 May 2023
- Published by Uniao Atlantica de Pesquisadores in Peer Review
- Vol. 5 (10) , 273-297
Mapeamento das intoxicações por agroquímicos no estado do Paraná
Todos os casos de intoxicação exógena são eventos de notificação compulsória, com preenchimento semanal do Sistema de Informação de Agravos de Notificação (Sinan), no entanto, uma estimativa de que apenas 20% dos casos são de fato notificados. Por meio de uma análise documental retrospectiva, descritiva, quantitativa, longitudinal entre 2015 e 2020, foi realizada a tabulação dos dados do Sinan, Siagro, ADAPAR e IBGE, e foram determinadas variáveis relevantes para a melhor compreensão do cenário paranaense atual quanto à comercialização e ao uso de agroquímicos, bem como às intoxicações exógenas. Obteve-se um cenário amplamente distorcido no que se refere à incidência geográfica dos agravos de saúde caracterizados como intoxicações exógenas, além disso, foi identificado um importante pico de notificações após a implantação da portaria que torna compulsória a notificação desse tipo de evento, ainda que haja uma importante incidência média de eventos cujas causas foram listadas como ignorado ou em branco (6,96%), além de volumes alarmantes de agroquímicos comercializados dentre as classes menos potencialmente.
- Open Access
- 24 June 2020
- Published by F1000 Research Ltd in F1000Research
- Vol. 9, 641
Prevalence of Alzheimer's disease according to anticholinesterase drug usage from 2012 to 2017 in the state of Paraná, Brazil
Introduction: Alzheimer's disease (AD) is a public health problem in Brazil due to the growing number of older adults in this population. Knowing the prevalence of AD in the Paraná state is essential to improve patients’ quality of life. The objective of the study was to estimate AD prevalence in the state of Paraná, based on the prescription of anticholinesterases, from 2012 to 2017. Methods: Patients diagnosed with AD, aged 60 years or over, who used Brazil’s Unified Public Health System (SUS) and received AD medication from the Department of Pharmaceutical Assistance of the state of Paraná, from 2012 to 2017, were the target population of the present study. The medication data were collected from the Computerized system management and Monitoring of Exceptional Drugs (SISMEDEX), and the population’s data were collected from the Brazilian Institute of Geography and Statistics (IBGE). Results: The sample consisted of 52,687 patients, and the median prevalence of AD in the established period for the state was 642.6/100,000 inhabitants (0.64%). In all ages and macro-regions, women showed the highest prevalence rates. The median prevalence for women in the established period was 755.4/100,000 inhabitants (0.75%). Among men, the median prevalence was 510.2/100,000 inhabitants (0.51%). In the temporal analysis of prevalence, between 2012 and 2017, a reduction of 23% was found in the state rate. The prevalence rate of Paraná for AD is nine times lower than the Brazilian average. Conclusions: Paraná’s prevalence rate for AD is lower than the rates of Brazil and the world, suggesting that AD is underdiagnosed in most municipalities of this state.
- 24 June 2020
- Published by F1000 Research Ltd in F1000Research
- Vol. 9, 641
Open AccessPrevalence of Alzheimer's disease according to anticholinesterase drug usage from 2012 to 2017 in the state of Paraná, Brazil
Introduction: Alzheimer's disease (AD) is a public health problem in Brazil due to the growing number of older adults in this population. Knowing the prevalence of AD in the Paraná state is essential to improve patients’ quality of life. The objective of the study was to estimate AD prevalence in the state of Paraná, based on the prescription of anticholinesterases, from 2012 to 2017. Methods: Patients diagnosed with AD, aged 60 years or over, who used Brazil’s Unified Public Health System (SUS) and received AD medication from the Department of Pharmaceutical Assistance of the state of Paraná, from 2012 to 2017, were the target population of the present study. The medication data were collected from the Computerized system management and Monitoring of Exceptional Drugs (SISMEDEX), and the population’s data were collected from the Brazilian Institute of Geography and Statistics (IBGE). Results: The sample consisted of 52,687 patients, and the median prevalence of AD in the established period for the state was 642.6/100,000 inhabitants (0.64%). In all ages and macro-regions, women showed the highest prevalence rates. The median prevalence for women in the established period was 755.4/100,000 inhabitants (0.75%). Among men, the median prevalence was 510.2/100,000 inhabitants (0.51%). In the temporal analysis of prevalence, between 2012 and 2017, a reduction of 23% was found in the state rate. The prevalence rate of Paraná for AD is nine times lower than the Brazilian average. Conclusions: Paraná’s prevalence rate for AD is lower than the rates of Brazil and the world, suggesting that AD is underdiagnosed in most municipalities of this state.
- Open Access
- 1 February 2019
- Published by FapUNIFESP (SciELO) in Revista da Associação Médica Brasileira
- Vol. 65 (2) , 222-231
Nutritional and hematological factors associated with the progression of Alzheimer's disease: a cohort study
SUMMARY OBJECTIVE: We studied the users of the Specialized Drug Distribution Program of the public health network. METHODS: A prospective cohort examined the elderly at two intervals of three years and included 30 patients in phase I and 16 in phase II. The methodology was composed of home visits, anthropometric, nutritional and hematological evaluation. For the progression of AD, the Clinical Dementia Rating (CDR) scale was used. RESULTS: According to the CDR, the disease evolved, since in 2014 most of the patients were in CDR 3. In the analysis of the micronutrients, only the B vitamins (B1, B2, B3, B5, B6) presented a significant reduction in 2014. The consumption of carbohydrates and lipids increased in the 2014 evaluation, and protein consumption decreased. As for the average weight of the elderly, there was an increase in 2014, 65.9 (± 15.6) Kg, with a BMI of 26.75 (± 4, 5), in 2011 the average weight was 62.44 kg (± 14, 36), BMI 24.64 (± 4.97). CONCLUSION: The hypothesis that patients are likely to be overweight or obese before the development of AD and that this may be associated with an increased risk of dementia is suggested.
- 1 February 2019
- Published by FapUNIFESP (SciELO) in Revista da Associação Médica Brasileira
- Vol. 65 (2) , 222-231
Open AccessNutritional and hematological factors associated with the progression of Alzheimer's disease: a cohort study
SUMMARY OBJECTIVE: We studied the users of the Specialized Drug Distribution Program of the public health network. METHODS: A prospective cohort examined the elderly at two intervals of three years and included 30 patients in phase I and 16 in phase II. The methodology was composed of home visits, anthropometric, nutritional and hematological evaluation. For the progression of AD, the Clinical Dementia Rating (CDR) scale was used. RESULTS: According to the CDR, the disease evolved, since in 2014 most of the patients were in CDR 3. In the analysis of the micronutrients, only the B vitamins (B1, B2, B3, B5, B6) presented a significant reduction in 2014. The consumption of carbohydrates and lipids increased in the 2014 evaluation, and protein consumption decreased. As for the average weight of the elderly, there was an increase in 2014, 65.9 (± 15.6) Kg, with a BMI of 26.75 (± 4, 5), in 2011 the average weight was 62.44 kg (± 14, 36), BMI 24.64 (± 4.97). CONCLUSION: The hypothesis that patients are likely to be overweight or obese before the development of AD and that this may be associated with an increased risk of dementia is suggested.
- Open Access
- 1 February 2018
- Published by F1000 Research Ltd in F1000Research
- Vol. 7, 137
Nutritional status, survival and mortality in Alzheimer patients - a cross-sectional study
Introduction: Dementia is a common health problem in elderly people, Alzheimer disease (AD) being the most prevalent. AD can be considered as a cause of death and must be registered on the death certificate of the patients. However, most of the time, the main cause of death registered is not related to AD, but as an underlying or contributing cause. For example, individuals who have AD and die from myocardium infarction. This study aimed to analyze if nutritional status was associated with survival and mortality for AD, and if AD was reported as actual cause of death on the death certificate Methods: The study was carried out as a cross-sectional study with elderly citizens of the community registered in the National Health System (SUS), with cognitive, nutritional, biochemical and hematological evaluations of 30 AD patients in Guarapuava, Paraná state, Brazil. Results: Significant differences were not observed between live and dead patients when evaluated considering the methods applied. Only 22% of the death certificates stated death due to AD. The patient’s cause of death showed a strong relation to respiratory issues; potential explanations based on immunological, biochemical and comorbidity were not confirmed on this study. Conclusions: AD was not declared as the cause of death in the majority of certificates, contributing to the underreporting and reducing the information of death due to AD in the country.
- 1 February 2018
- Published by F1000 Research Ltd in F1000Research
- Vol. 7, 137
Open AccessNutritional status, survival and mortality in Alzheimer patients - a cross-sectional study
Introduction: Dementia is a common health problem in elderly people, Alzheimer disease (AD) being the most prevalent. AD can be considered as a cause of death and must be registered on the death certificate of the patients. However, most of the time, the main cause of death registered is not related to AD, but as an underlying or contributing cause. For example, individuals who have AD and die from myocardium infarction. This study aimed to analyze if nutritional status was associated with survival and mortality for AD, and if AD was reported as actual cause of death on the death certificate Methods: The study was carried out as a cross-sectional study with elderly citizens of the community registered in the National Health System (SUS), with cognitive, nutritional, biochemical and hematological evaluations of 30 AD patients in Guarapuava, Paraná state, Brazil. Results: Significant differences were not observed between live and dead patients when evaluated considering the methods applied. Only 22% of the death certificates stated death due to AD. The patient’s cause of death showed a strong relation to respiratory issues; potential explanations based on immunological, biochemical and comorbidity were not confirmed on this study. Conclusions: AD was not declared as the cause of death in the majority of certificates, contributing to the underreporting and reducing the information of death due to AD in the country.
- Open Access
- 29 November 2017
- Published by F1000 Research Ltd in F1000Research
- Vol. 6, 2068
Polypharmacy in Alzheimer's disease patients in Brazil: Guidance for pharmaceutical assistance
Background: Elderly patients frequently have concomitant diseases, triggering the necessity of utilizing several different medications, which can cause adverse events associated with therapy, called polypharmacy. This study aimed to evaluate the main concomitant diseases with Alzheimer's disease (AD) and discuss possible interactions between drugs utilized to treat dementia and its comorbidities, and indicate safe medicines for patients with AD. Methods: 41 individuals with AD who withdraw medicines for dementia from the Brazilian public health system (SUS) participated in this study. Data collection was performed using three questionnaires: 1) Clinical Dementia Rating, to verify disease stage; 2) Mini–mental state examination, to measure cognitive impairment; and 3) Sociodemographic analysis, to evaluate concomitant diseases, utilized drugs, drug-drug interactions, among other demographic variables. Statistical analyses were performed using SPSS and data was presented as relative frequency. Results: The results of this study showed that the most frequent concomitant diseases with AD are: systemic arterial hypertension, depression, diabetes mellitus, and hypercholesterolemia. Polypharmacy was observed in 95.12% of patients. The pharmacologic classes that presented interactions with AD medications were anxiolytics, antidepressants, antipsychotics, antihypertensives, and antidiabetics. Conclusion: In the present study, polypharmacy in patients with AD and other concomitant diseases has been characterized. The average number of drugs that these patients ingested was seven per day, and this leads to drug interactions, which are potentially damaging to the body. Consequently, we have tried to reduce these interactions, by suggesting drugs that are safer, for example furosemide instead of amlodipine to treat hypertension.
- 29 November 2017
- Published by F1000 Research Ltd in F1000Research
- Vol. 6, 2068
Open AccessPolypharmacy in Alzheimer's disease patients in Brazil: Guidance for pharmaceutical assistance
Background: Elderly patients frequently have concomitant diseases, triggering the necessity of utilizing several different medications, which can cause adverse events associated with therapy, called polypharmacy. This study aimed to evaluate the main concomitant diseases with Alzheimer's disease (AD) and discuss possible interactions between drugs utilized to treat dementia and its comorbidities, and indicate safe medicines for patients with AD. Methods: 41 individuals with AD who withdraw medicines for dementia from the Brazilian public health system (SUS) participated in this study. Data collection was performed using three questionnaires: 1) Clinical Dementia Rating, to verify disease stage; 2) Mini–mental state examination, to measure cognitive impairment; and 3) Sociodemographic analysis, to evaluate concomitant diseases, utilized drugs, drug-drug interactions, among other demographic variables. Statistical analyses were performed using SPSS and data was presented as relative frequency. Results: The results of this study showed that the most frequent concomitant diseases with AD are: systemic arterial hypertension, depression, diabetes mellitus, and hypercholesterolemia. Polypharmacy was observed in 95.12% of patients. The pharmacologic classes that presented interactions with AD medications were anxiolytics, antidepressants, antipsychotics, antihypertensives, and antidiabetics. Conclusion: In the present study, polypharmacy in patients with AD and other concomitant diseases has been characterized. The average number of drugs that these patients ingested was seven per day, and this leads to drug interactions, which are potentially damaging to the body. Consequently, we have tried to reduce these interactions, by suggesting drugs that are safer, for example furosemide instead of amlodipine to treat hypertension.